Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled
11 déc. 2023 01h00 HE
|
Azafaros BV
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled Topline data from the study, expected for mid-2024, will support two pivotal Phase...
Epigenetics Market revenue to hit USD 5 Billion by 2035, says Research Nester
07 nov. 2023 07h00 HE
|
Research Nester
New York , Nov. 07, 2023 (GLOBE NEWSWIRE) -- The global epigenetics market size is poised to grow at a CAGR of over 17% from 2023 to 2035. The market is anticipated to garner a revenue of USD 5...
Orphan Drugs Market Is Projected to Gain $4,35,686.3 Million By 2030, Claims Allied Market Research
23 oct. 2023 23h05 HE
|
Allied Market Research
Wilmington, Delaware, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Allied Market Research's report provided an estimation of the global orphan drugs market size estimated at $1,40,000.0 million in 2020 and is...
Artificial Intelligence in Drug Discovery Market Size & Share to Surpass $4197.5 Million by 2028 | Vantage Market Research
02 févr. 2023 06h18 HE
|
Vantage Market Research
WASHINGTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- According to the report published by Vantage Market Research, the Global Artificial Intelligence (AI) in Drug Discovery Market garnered $ 627.1 Million...
Global Orphan Drugs Market to Reach USD 3,199.3 Million by 2028; Increasing Prevalence of Rare Diseases among Global Population Driving the Orphan Drugs Market, States Vantage Market Research
17 nov. 2021 14h25 HE
|
Vantage Market Research
WASHINGTON, Nov. 17, 2021 (GLOBE NEWSWIRE) -- The global orphan drugs market size is expected to reach USD 3,199 Million by 2028, exhibiting a CAGR of 7.4% during the forecast period. Increasing...
Artificial Intelligence in Drug Discovery Market To Reach USD 2.13 Billion By 2027 | Reports and Data
23 avr. 2020 15h00 HE
|
Reports and Data
New York, April 23, 2020 (GLOBE NEWSWIRE) -- According to Reports and Data, the Artificial Intelligence in Drug Discovery Market was valued at USD 253.8 million in 2019 and is expected to reach USD...
Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
20 juil. 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering
17 juil. 2018 18h55 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
21 juin 2018 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
18 juin 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...